$KRYS SEC Filings

Filed On	Filing
15 Oct 2026	8-K: Regulation FD Disclosure Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113
16 Sep 2026	Form 4: Mazzacco Catherine, Director Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units
16 Sep 2026	Form 4: Sutherland Everett Rand, Director Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units
16 Sep 2026	Form 4: Mason Christopher, Director Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units
16 Sep 2026	Form 4: Janney Daniel, Director Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Award
16 Sep 2026	Form 4: Gangolli Julian S, Director Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units
16 Sep 2026	Form 4: Rossi Dino A, Director Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units
04 Sep 2026	144
04 Sep 2026	144
04 Sep 2026	Form 4: Krishnan Suma, Director Sold 25,000 shares ($8.98M)
04 Sep 2026	Form 4: Krishnan Krish S, Director Sold 25,000 shares ($8.98M)
14 Aug 2026	Form 4: Rossi Dino A, Director Gave 3,691 shares as a gift · Sold 25,000 shares ($8.23M)
14 Aug 2026	144
03 Aug 2026	10-Q
03 Aug 2026	8-K: Results of Operations and Financial Condition
21 Jul 2026	8-K: Other Events
26 Jun 2026	Form 4: Thomas John Charles, EVP, General Counsel Received 1,000 shares by exercise or conversion ($179K) · Sold 1,000 shares ($347K)
25 Jun 2026	144
05 Jun 2026	Form 4: Krishnan Suma, Director Sold 25,000 shares ($7.7M)
05 Jun 2026	Form 4: Krishnan Krish S, Director Sold 25,000 shares ($7.7M)

Comments